Evidence map›Paper›PMID 30094041›Full record

ArticleLupus science & medicine2018

DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity.

Cristina M Lanata, Sharon A Chung, Lindsey A Criswell

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Current Research in Drug-Free Cancer Therapies.Bioengineering (Basel, Switzerland) · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Functional Consequences Paternal Preconceptual Alcohol Consumption.Current topics in behavioral neurosciences · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Cristina M LanataRussell/Engleman Rheumatology Research Center, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Sharon A ChungRussell/Engleman Rheumatology Research Center, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Lindsey A CriswellRussell/Engleman Rheumatology Research Center, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Racial/ethnic and socioeconomic disparities in biologic and clinical SLE outcomesU01DP005120 · DP · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALL'ERA, MARIA, YAZDANY, JINOOS · 2014 to 2018
$4.8M
ACL HHS U01DP005120NCCDPHP CDC HHS U01 DP005120NIAMS NIH HHS P30 AR070155
6 · The paper itself

Abstract

SLE is a complex autoimmune disease that results from the interplay of genetics, epigenetics and environmental exposures. DNA methylation is an epigenetic mechanism that regulates gene expression and tissue differentiation. Among all the epigenetic modifications, DNA methylation perturbations have been the most widely studied in SLE. It mediates processes relevant to SLE, including lymphocyte development, X-chromosome inactivation and the suppression of endogenous retroviruses. The establishment of most DNA methylation marks occurs in utero; however, a small percentage of epigenetic marks are dynamic and can change throughout a person's lifetime and in relation to exposures. In this review, we discuss the current understanding of the biology of DNA methylation and its regulators, the measurement and interpretation of methylation marks, the effects of genetics on DNA methylation and the role of environmental exposures with relevance to SLE. We also summarise research findings associated with SLE disease risk and heterogeneity. The robust finding of hypomethylation of interferon-responsive genes in patients with SLE and new associations beyond interferon-responsive genes such as cell-specific methylation abnormalities are described. We also discuss methylation changes associated with lupus nephritis, autoantibody status and disease activity. Lastly, we explore future research directions, emphasising the need for longitudinal studies, cell tissue and context-specific profiling, as well as integrative approaches. With new technologies, DNA methylation perturbations could be targeted and edited, offering novel therapeutic approaches.

Indexed as

DNA methyationenvironmental exposuressystemic lupus erythematosus

Identifiers

PMID30094041
PMCPMC6069928
OpenAlexW2883303482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.